Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results, Beats Expectations By $0.08 EPS

Anebulo Pharmaceuticals (NASDAQ:ANEB) announced its earnings results on Wednesday. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Price Performance

ANEB traded up $0.09 on Friday, hitting $2.05. 9,487 shares of the stock were exchanged, compared to its average volume of 6,878. Anebulo Pharmaceuticals has a 12 month low of $1.62 and a 12 month high of $3.61. The business has a 50-day moving average of $2.05 and a two-hundred day moving average of $2.35. The firm has a market capitalization of $53.16 million, a price-to-earnings ratio of -5.68 and a beta of -1.01.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.